Annals of emergency medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Ecallantide for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Multicenter, Randomized, Controlled Trial.
We compare the safety and efficacy of ecallantide with placebo in subjects undergoing assessment for acute angiotensin-converting enzyme inhibitor-induced angioedema (ACEIA) in an emergency department (ED). ⋯ The addition of ecallantide to standard therapy does not appear to improve angioedema compared with placebo in ED patients with ACEIA. Our data suggest that most ED patients presenting with mild to moderate ACEIA are likely to meet our discharge eligibility criteria within 6 hours of treatment, regardless of intervention. Further studies to assess the utility of ecallantide in patients with more severe angioedema may be useful. No new safety signals related to ecallantide administration were identified.